Estimated antiretroviral therapy coverage among people living with HIV in Guyana
Guyana: Estimated antiretroviral therapy coverage among people living with HIV was 69.0% in 2025. ◆ Volatile
Estimated antiretroviral therapy coverage among people living with HIV in Guyana, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, estimated antiretroviral therapy coverage among people living with hiv in Guyana stood at 69.0%.
The figure is down 2.8% on the previous year and up 23.2% over ten years.
Over the whole period, estimated antiretroviral therapy coverage among people living with hiv in Guyana peaked at 71.0% in 2024 and was at its lowest, 0.0%, in 2000.
Guyana ranks 87th of 143 countries on this measure, in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Estimated antiretroviral therapy coverage among people living with HIV in Guyana, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 0.0% | — |
| 2001 | 0.0% | — |
| 2002 | 0.0% | — |
| 2003 | 2.0% | — |
| 2004 | 9.0% | +350.0% |
| 2005 | 21.0% | +133.3% |
| 2006 | 27.0% | +28.6% |
| 2007 | 31.0% | +14.8% |
| 2008 | 38.0% | +22.6% |
| 2009 | 42.0% | +10.5% |
| 2010 | 43.0% | +2.4% |
| 2011 | 47.0% | +9.3% |
| 2012 | 49.0% | +4.3% |
| 2013 | 52.0% | +6.1% |
| 2014 | 54.0% | +3.8% |
| 2015 | 56.0% | +3.7% |
| 2016 | 59.0% | +5.4% |
| 2017 | 61.0% | +3.4% |
| 2018 | 60.0% | -1.6% |
| 2019 | 64.0% | +6.7% |
| 2020 | 62.0% | -3.1% |
| 2021 | 63.0% | +1.6% |
| 2022 | 65.0% | +3.2% |
| 2023 | 67.0% | +3.1% |
| 2024 | 71.0% | +6.0% |
| 2025 | 69.0% | -2.8% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 17.0% | 0.0% | 42.0% | 10 |
| 2010s | 54.5% | 43.0% | 64.0% | 10 |
| 2020s | 66.2% | 62.0% | 71.0% | 6 |
Countries ranked near Guyana
More health data for Guyana
- Un projection of annual infant deaths, annual growth rate -1.59 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.4509 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,225 deaths per 1,000 people (2090)
- Number of infants who die before age 1 62 deaths (2100)
- Population ages 05-09, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 05-09, female, per capita 0.0482 units per person (2025)
- Population ages 05-09, male, annual growth rate 0.0265 % change on previous year (2025)
- Population ages 05-09, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 05-09, male, per capita 0.0497 units per person (2025)
- Population ages 10-14, female, annual growth rate 0.8539 % change on previous year (2025)
Frequently asked questions
- What is estimated antiretroviral therapy coverage among people living with hiv in Guyana?
- Estimated antiretroviral therapy coverage among people living with hiv in Guyana was 69.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest estimated antiretroviral therapy coverage among people living with hiv recorded in Guyana?
- The highest recorded value was 71.0% in 2024.
- What is the lowest estimated antiretroviral therapy coverage among people living with hiv recorded in Guyana?
- The lowest recorded value was 0.0% in 2000.
- How does Guyana rank for estimated antiretroviral therapy coverage among people living with hiv?
- Guyana ranks 87th out of 143 countries with data for 2025.
- Is estimated antiretroviral therapy coverage among people living with hiv rising or falling in Guyana?
- Over the last ten years it is up 23.2%. The long-run trend across the full record is volatile.
- Where does this Guyana data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Estimated antiretroviral therapy coverage among people living with HIV (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).